ABCL
What one share of AbCellera Biologics holds
Pharmaceutical Preparations
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates.
AbCellera Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.22 |
|---|---|
| Profit | −$0.55 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$0.40 |
| Cash and investments | $0.39 |
| Book value | $2.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.08 | −$0.01 | $0.03 | −$0.01 | — | $0.07 |
| 2020 | $0.89 | $0.45 | $0.04 | $0.05 | — | $3.08 |
| 2021 | $1.18 | $0.48 | $0.18 | $0.58 | — | $3.62 |
| 2022 | $1.54 | $0.50 | $0.22 | $0.66 | — | $4.30 |
| 2023 | $0.13 | −$0.51 | $0.27 | −$0.42 | — | $3.96 |
| 2024 | $0.10 | −$0.55 | $0.27 | −$0.64 | — | $3.57 |
| 2025 | $0.25 | −$0.49 | $0.14 | −$0.58 | — | $3.22 |